Phantom Neuro Raises $3.26M for Robotic Orthopedic Technologies
- Funding

Phantom Neuro Raises $3.26M for Robotic Orthopedic Technologies

Neurotechnology Startup Phantom Neuro Secures $3.26M Seed Round from LionBird Ventures, Draper Associates & Breakout Ventures to Advance Machine Control Technology

With Over 50 Years of Collective Research Experience, Founder and Co-Inventors Grow Technological Capabilities, Build Out System for Lifelike Control of Robotic Prosthetic Limbs and Exoskeletons

AUSTIN, Texas and BALTIMORE, Md.March 25, 2022 /PRNewswire/ — Phantom Neuro, a burgeoning neurotechnology startup that delivers low power, high accuracy system for lifelike control of robotic orthopedic technologies, today announced a $3.26 million funding round from leading international and U.S.-based investors. LionBird Ventures, headquartered in Tel Aviv and a leader in identifying winning pre-scale digital health companies, led the round with participation from Draper Associates, Breakout Ventures, Blackrock Neurotech, and Capital Factory, along with private investors. With the funding, LionBird Ventures’ Partner Robert Lord will join the Phantom Neuro board, and Managing Partner Ed Michael will join as a board observer.

“Our patent-pending Phantom X technology offers enhanced control of current and next-generation robotic orthopedic mechanisms, such as prosthetics and exoskeletons. In allowing patients greater control of these lifelike extensions of their person, we are providing those we treat with the ability to return to the activities and lifestyles that they know and love,” said Dr. Connor Glass, Founder, and CEO of Phantom Neuro and primary inventor of Phantom’s technology.

Advancements in robotics have yet to tangibly reduce the medical and financial burdens associated with limb injury despite dramatic improvements in prosthetic and exoskeleton capabilities. For example, a 2020 Veterans Affairs study found no difference in user satisfaction between robotic, standard, and cosmetic upper limb prosthetics. A 2019 national survey of veterans with amputation demonstrated that only 60% of upper limb amputees use a prosthesis. In addition, a 2020 CDC report found that in any given year, 25% of people over the age of 65 report at least one major fall, with non-fatal falls costing the US health system $50 billion annually. At the same time, advanced exoskeletons exist that could theoretically reduce the risk of these falls and improve walking function. Phantom Neuro seeks to bridge the gap between these technologies and the average intended user who has yet to see a significant improvement in quality of life.

See also  Healthy.Capital Invests in Nori Health to fight Chronic Bowel Disease

“When LionBird was first introduced to the Phantom Neuro team, they had been hard at work on their technology for more than two years,” said Robert Lord, partner at LionBird. “What started as an invention out of Johns Hopkins to bridge the gap between available technology and limb injury patients’ expected outcomes has turned into a promising neurotechnology startup; as investors, we are eager for this opportunity to support an all-star team and help reset healthcare’s relationship with technology by scaling Phantom Neuro’s sophisticated platform to serve deserving patient populations ultimately.”

After completing his medical degree at the University of Oklahoma College of Medicine, Dr. Connor Glass took up a research fellowship at The Johns Hopkins University School of Medicine’s Department of Plastic and Reconstructive Surgery, where he sought to study advanced microsurgery treatments for function loss and neuropathic pain, intending to pursue a career in plastic surgery. It was then that the vast gap between the technological advancements that had piqued his interest in the field became evident from the reality of expected outcomes in the general population.

About Phantom Neuro
Phantom is creating a system that will enable lifelike control of robotic orthopedic technologies, such as prosthetic limbs and exoskeletons. Phantom’s solution consists of low-risk implantable sensors, Ai, and enabling software. This solution will provide superior control of existing and next-generation orthopedic technologies and grow into a platform for lifelike control of virtually any wireless compatible device. You can find out more at

About LionBird
LionBird is a venture capital firm investing in pre-scale digital health companies with operations in Tel Aviv and the US. Founded in 2012 by veteran entrepreneurs and Fortune 100 executives in the software and healthcare industries, LionBird provides pre-scale capital and assistance to mission-driven teams realigning the human-technology relationship in healthcare. Since its inception, the firm has invested in more than 30 founding teams across the US and Israel. The firm is investing out of its third fund, LionBird III, exclusively focused on early-stage digital health.

See also  Electric Hydrogen Closes $24M Series A to Enable Deep Decarbonization

Phantom Neuro Raises $3.26M for Robotic Orthopedic Technologies.